• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lexeo Therapeutics, Inc. - Common Stock (NQ: LXEO )

    11.19 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 44
    Open 11.19
    Bid (Size) 4.480 (2)
    Ask (Size) 12.85 (1)
    Prev. Close 11.19
    Today's Range 11.19 - 11.19
    52wk Range 9.000 - 22.33
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Crude Oil Moves Lower; Goldman Sachs Posts Upbeat Results
    Via Benzinga
    Exposures Fossil Fuels
    Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga

    Performance

    YTD
    -24.54%
    -24.54%
    1 Month
    -30.93%
    -30.93%
    3 Month
    -11.61%
    -11.61%
    6 Month
    -33.59%
    -33.59%
    1 Year
    +11.34%
    +11.34%

    More News

    Read More
    Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet
    Via Benzinga
    Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout
    Via Investor's Business Daily
    Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
    From Lexeo Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics to Participate in Upcoming Investor Conferences
    From Lexeo Therapeutics
    Via GlobeNewswire
    Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
    From Lexeo Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
    From Lexeo Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
    From Lexeo Therapeutics
    Via GlobeNewswire
    RBC Capital Maintains Outperform Rating for Lexeo Therapeutics: Here's What You Need To Know
    Via Benzinga
    Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
    From Lexeo Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
    From Lexeo Therapeutics
    Via GlobeNewswire
    Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
    From Lexeo Therapeutics
    Via GlobeNewswire
    Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Fastenal Posts Upbeat Earnings, Joins NovoCure, Taiwan Semiconductor Manufacturing And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From LEXEO Therapeutics
    Via GlobeNewswire
    Marathon Digital, Canaan, CleanSpark And Other Big Stocks Moving Lower On Tuesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
    From LEXEO Therapeutics
    Via GlobeNewswire
    LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023
    Via InvestorPlace
    Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
    From LEXEO Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Pineapple Financial Drops In Trading Debut
    Via Talk Markets
    Topics Initial Public Offering
    Exposures Securities Market
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.